Dr. Keith Wilson on the Role of Helicobacter Pylori in Gastrointestinal Cancer
<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>
Keith Wilson, MD, senior professor of Medicine (Gastroenterology, Hepatology & Nutrition), professor of Cancer Biology, Vanderbilt University Medical Center discusses the role helicobacter pylori plays in gastrointestinal cancer and what the next steps could be in better targeting this bacteria.
Wilson said in his research, he and his team have found that the bacteria alters the way its host recognizes it and essentially disables the human body's ability to kill it. Wilson says his research has revealed a unique oxidative pathway that may be utilized to not only kill the bacteria, but help inflammation in patients with gastric cancer.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
